Genital Herpes Vaccine is in Development; CBCD Congratulates Genocea (GNCA) Research Team

Industry: Health & Fitness

The CBCD congratulates Genocea Biosciences (GNCA) on the commencement of new clinical trials for a vaccine candidate against the genital herpes virus.

New York (PRUnderground) August 17th, 2014

“Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR.”  – Greg Bennett, CBCD

Currently there are no vaccines approved to protect against the genital herpes virus (HSV-2). However, Genocea Biosciences, a biotech company, recognized this need and has been working on such a vaccine. Dr. Seth Hetherington, MD, chief medical officer of Genocea announced that their new vaccine candidate against the genital herpes virus is entering phase 2 clinical trials. Chip Clark, president and chief executive officer of Genocea said that “We believe that there is a significant clinical need for an effective immunotherapy to treat HSV-2. Our market research supports that both patients and physicians would welcome a new treatment, such as GEN-003, with efficacy similar to oral antivirals, sustained duration of protection and enhanced convenience through simplified dosing.” (1) The CBCD looks forward to seeing the results of the GEN-003 HSV-2 vaccine trials in 2015.

The CBCD congratulates Genocea’s researchers since HSV-2 “is generally considered as a common chronic STD in both developed and developing countries with substantial morbidity.” (2) However, the Center reminds the public that an FDA approved vaccine against the genital herpes virus may take some time to reach the market. This means that it may be a while before the public can take advantage of such a vaccine. Until then, the CBCD recommends two natural, safe and effective, HSV-2 remedies that are backed by clinical studies.

Click to learn more about genital herpes symptoms.

The Center for the Biology of Chronic Disease (CBCD) therefore recommends that people infected with the genital herpes virus (HSV-2) take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes simplex virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs.  Study authors wrote that, “individuals infected with the HSV … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3)  The study authors also wrote that, “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Until now, drugs approved for the treatment of HSV-2 infections include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.” (3) There are also natural remedies that target the latent HSV. Two of these clinically backed remedies are Novirin and Gene-Eden-VIR.

The CDC notes that “Genital herpes is common in the United States. In the United States, about one out of every six people aged 14 to 49 years have genital herpes. You can get herpes by having vaginal, anal, or oral sex with someone who has the disease.

Fluids found in a herpes sore carry the virus, and contact with those fluids can cause infection. You can also get herpes from an infected sex partner who does not have a visible sore or who may not know he or she is infected because the virus can be released through your skin and spread the infection to your sex partner(s).” (4)

“There are currently no FDA approved vaccines against the genital herpes virus. Research shows that most drugs against HSV-2 only reduce outbreaks by one day. Thus, we recommend that infected individuals take Novirin or Gene-Eden-VIR, which are designed to help the immune system target the latent HSV-2.” – Greg Bennett, CBCD

Click to learn more about Novirin and Genital Herpes, and Gene-Eden-VIR and Genital Herpes.

References:

(1) Marketwatch.com – The Wall Street Journal – Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy. Published on July 21, 2014.

(2) Mehrabani D1, Behzadi MA2, Azizi S3, Payombarnia H3, Vahdani A3, Namayandeh M2, Ziyaeyan M2. Cervical Infection with Herpes simplex Virus, Chlamydia trachomatis, and Neisseria gonorrhoeae among Symptomatic Women, Dubai, UAE: A Molecular Approach. Interdiscip Perspect Infect Dis. 2014;2014:347602.

(3) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

(4) CDC.com – Genital Herpes – CDC Fact Sheet. Last updated on July 1, 2014.

 

About CBCD

About CBCD

The Center for the Biology of Chronic Disease (http://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c) 3 of the IRS tax code. The center’s mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases. The CBCD first published Dr. Hanan Polansky’s highly acclaimed “Purple” book, entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” in 2003. In this book, he explains how foreign DNA fragments can cause many major diseases. The book has been read by more than 5,000 scientists around the world, and has been reviewed in more than 20 leading scientific journals. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Become a Fan

Press Contact

Name
Mike Evans
Phone
585-250-9999
Email
note
3d77f86c86f5f460a31502d024f72c2a
@buy-gene-eden.com
Website
http://www.gene-eden-vir.com

Video

Website